Gunderson Dettmer acted as legal advisor to ARMO BioSciences (ARMO) in its $1.6 billion acquisition by Eli Lilly and Company (Lilly). In a definitive agreement announced today, the all-cash transaction will bolster Lilly’s immune-oncology program through the addition of ARMO’s lead product, pegilodecakin, which has demonstrated clinical benefit in multiple tumor types. The Gunderson Dettmer deal team, which has worked with ARMO since its inception, included: partner and Mergers and Acquisitions Chair Andrew Luh, partner Marcia Hatch, partner Sharon Hendricks, partner Gina Marek, special counsel Michael Richman, and associates Albert Vanderlaan, Albert Yeh, Colin Conklin, Kelly Trimble, Laurel Fedder and Matt Weber.

ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates designed to activate the immune system of cancer patients to recognize and eradicate tumors.

For further details, the official press release can be seen here.